(Total Views: 545)
Posted On: 12/20/2019 12:05:43 PM
Post# of 151

$MRK News Article - Merck's KEYTRUDA (pembrolizumab) Approved in Japan for Three New First-Line Indications Across Advanced Renal Cell Carcinoma (RCC) and Recurrent or Distant Metastatic Head and Neck Cancer https://marketwirenews.com/news-releases/merc...67956.html


My Twitter: WhyteStocks